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Introduction
Measures of lung function act as predictors of mortality and 
morbidity and form the basis for the diagnosis of several diseases, 
most notably chronic obstructive pulmonary disease (COPD), 
one of the leading causes of death globally1. Environmental 
factors, including smoking and exposure to air pollution play a 
significant role in lung function; however there has also 
been shown to be a genetic component, with estimates of the 
narrow sense heritability ranging between 39–66%2–5. Genome-
wide association studies (GWAS) of lung function have iden-
tified associations between single nucleotide polymorphisms 
(SNPs) and lung function at over 150 independent loci to date6–14. 
Associations have also been identified in GWAS of COPD15–19; 
however, the identification of disease associated SNPs has been 
restricted by limited sample sizes. Many signals first identi-
fied in powerful studies of quantitative lung function traits, have 
been found to be associated with risk of COPD, highlighting the 
potential clinical usefulness of comprehensive identification of 
lung function associated SNPs13.
Low frequency (minor allele frequency (MAF) 1–5%) and 
rare (MAF<1%) variants have been largely underexplored by 
GWAS to date. Exome arrays have been designed to facilitate the 
investigation of these low frequency and rare variants, predomi-
nately within coding regions, in large sample sizes. Alongside a 
core content of rare coding SNPs, the exome array additionally 
includes common variation, including tags for previously identi-
fied GWAS hits, ancestry informative SNPs, a grid of markers 
for estimating identity by descent and a random selection of 
synonymous SNPs20.
An earlier version of this article can be found on bioRxiv 
(https://doi.org/10.1101/164426)
Results
We carried out a meta-analysis of exome array data and three 
lung function measures: forced expiratory volume in one second 
(FEV1), forced vital capacity (FVC) and the ratio of FEV1 to FVC 
(FEV1/FVC). These analyses included 68,470 individuals from 
the SpiroMeta and CHARGE consortia in a discovery analysis, 
with follow-up in an independent sample of up to 111,556 indi-
viduals. All studies are listed with their study-specific sample 
characteristics in Table 1, with full study descriptions, including 
details of spirometry and other measurements described in the 
Supplementary Note. The genotype calling procedures imple-
mented by each study (Supplementary Table 1) and quality con-
trol of genotype data are described in the Supplementary Methods. 
We have undertaken both single variant analyses, and gene-based 
associations, which test for the joint effect of several rare variants 
in a gene (see Methods for details).
Meta-analyses of single variant associations
We first evaluated single variant associations between FEV1, FVC 
and FEV1/FVC and the 179,215 SNPs that passed study level 
quality control and were polymorphic in both consortia. These 
analyses identified 34 SNPs in regions not previously associated 
with lung function, showing association with at least one trait at 
overall P<10-5, and showing association with consistent direction 
and P<0·05 in both consortia (full results in Supplementary 
Table 2, quantile-quantile and Manhattan plots shown in 
Supplementary Figure 1). We followed up these SNP associations 
in a replication analysis comprising 3 studies with 111,556 indi-
viduals. Combining the results from the discovery and replication 
stages in a meta-analysis identified six SNPs in total that were 
independent to known signals and met the pre-defined signifi-
cance threshold (P<2·8×10-7) overall in, or near to FGF10, LY86, 
SEC24C, RPAP1, CASC17 and UQCC1 (Table 2, Supplementary 
Figure 2). A SNP near to the CASC17 signal (rs11654749, r2=0·3 
with rs1859962) has previously been associated with FEV1 in a 
genome-wide analysis of gene-smoking interactions, although 
this association was not replicated at the time21; the present 
analysis provides the first evidence for independent replication of 
this signal. A seventh signal was also identified in LCT (Table 2, 
Supplementary Figure 2); whilst this locus has not previously 
been implicated in lung function, this SNP is known to vary in 
frequency across European populations22, and we cannot rule out 
that this association is not an artefact of population structure. 
Our discovery analysis furthermore identified associations 
(P<10-5) in 25 regions previously associated with one or more 
of FEV1, FVC and FEV1/FVC (Supplementary Table 3).
Generally, the observed effect of the SNPs at the novel signals 
were similar in ever and never smokers; the exception was 
rs1448044 near FGF10, which showed a significant association 
with FVC only in ever smokers in our discovery analysis (ever 
smokers P=1·49×10-6; never smokers P=0·695, Supplementary 
Table 4 and Supplementary Figure 3). In the replication analysis, 
however, this association was observed in both ever and 
never smokers (ever smokers P=3·14×10-5; never smokers 
P=1·40×10-4, Supplementary Table 5). For rs1200345 (RPAP1) 
and rs1859962 (CASC17), associations were most statistically 
significant in the analyses restricted to individuals of European 
Ancestry (Supplementary Table 4 and Supplementary Figure 3), as 
was the association with rs2322659 (LCT), giving further support 
that this association may be due to population stratification.
Meta-analyses of gene-based associations
We undertook Weighted Sum Tests (WST)23 and Sequence 
Kernel Association tests (SKAT)24 to assess the joint effects of 
multiple low frequency variants within genes on lung function 
traits. In our discovery analyses of all 68,470 individuals, we tested 
up to 14,380 genes that had at least two variants with MAF<5% 
and met the inclusion criteria (exonic or loss of function [LOF], 
see Methods for definitions) in both consortia. The SKAT analy-
ses identified 16 genes associated (P<0·05 in both consortia and 
overall P<10-4) with FEV1, FVC or FEV1/FVC (Supplementary 
Table 6), whilst the WST analyses identified 12 genes 
            Amendments from Version 2
We have added a further limitation to the discussion of the 
paper outlining a recently highlighted issue regarding the trait 
transformation undertaken in our replication analyses. We show 
through sensitivity analyses that our results are not affected by 
this issue (Supplementary Figure 4), but note that future studies 
should avoid such a transformation.
See referee reports
REVISED
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1958 British Birth Cohort (B58C) 5270 2961 (56·2%) 2866 (53·3%) 44·00 (0·00) 3·35 (0·79) 4·29 (1·03) 0·788 (0·09)
Generation Scotland (GS:SFHS) 8164 3413 (41·8%) 3806 (46·6%) 51·59 (13·33) 2·78 (0·87) 3·91 (1·01) 0·710 (0·12)
Cooperative Health Research in the 
Region of Augsburg (KORA F4)
1447 701 (48·5%) 900 (62·2%) 54·82 (9·66) 3·24 (0·85) 4·20 (1·04) 0·771 (0·07)
CROATIA-Korcula cohort 
(KORCULA)
791 296 (36·8%) 418 (52·0%) 55·56 (13·69) 2·72 (0·83) 3·29 (0·95) 0·829 (0·10)
Lothian Birth Cohort 1936 
(LBC1936)
974 501 (50·6%) 554 (55·9%) 69·55 (0·84) 2·38 (0·67) 3·04 (0·87) 0·787 (0·10)
Study of Health in Pomerania 
(SHIP)
1681 831 (49·4%) 955 (56·8%) 52·25 (13·43) 3·29 (0·88) 3·88 (1·03) 0·848 (0·07)
Northern Swedish Population 
Health Study (NSPHS)
880 407 (46·3%) 122 (13·9%) 49·13 (19·96) 2·93 (0·90) 3·53 (1·06) 0·831 (0·09)
Prospective Investigation of the 
Vasculature in Uppsala Seniors 
(PIVUS)
836 413 (49·4%) 426 (51·0%) 70·20 (0·17) 2·44 (0·68) 3·20 (0·87) 0·76 (0·10)
Swiss study on Air Pollution and 
Lung Disease in adults (SAPALDIA)
2707 1379 (50·9%) 1399 (51·7%) 40·86 (10·92) 3·65 (0·83) 4·62 (1·04) 0·794 (0·07)
The Cardiovascular Risk in Young 
Finns Study (YFS)
434 198 (47·3%) 186 (44·4%) 38·88 (5·07) 3·73 (0·75) 4·68 (0·99) 0·800 (0·06)




















AGES-Reykjavik study (AGES) 1566 649 (41·4%) 900 (57·5%) 76·1 (5·62) 2·13 (0·70) 2·87 (0·86) 0·744 (0·09)
Atherosclerosis Risk in 
Communities Study (ARIC)
10,680 5015 (47·0%) 631 (59·1%) 54·3 (5·70) 2·94 (0·77) 3·98 (0·98) 0·738 (0·07)
Cardiovascular Health Study (CHS) 3967 1737 (43·8%) 2089 (52·7%) 72·8 (5·55) 2·11 (0·66) 3·00 (0·86) 0·702 (0·10)
NHLBI Family Heart Study (FAMHS) 1651 718 (43·5%) 698 (42·3) 53·5 (12·60) 2·91 
(0·853)
3·89 (1·05) 0·746 (0·08)
Framingham Heart Study (FHS) 7113 3241 (45·5%) 3780 (53·1) 50·7 (14·12) 3·10 
(0·925)
4·09 (1·12) 0·755 (0·08)
Health Aging and Body 
Composition Study (HABC)
1457 786 (53·2%) 831 (56·5%) 73·7 (2·83) 2·31 (0·66) 3·11 (0·81) 0·741 (0·08)
Health2006 Study 2714 1217 (44·8%) 1577 (58·1%) 49·4 (13·04) 3·13 (0·82) 3·99 (0·99) 0·784 (0·07)
Health2008 Study 687 297 (43·2%) 384 (55·9%) 46·7 (8·22) 3·27 (0·79) 4·13 (0·97) 0·791 (0·06)
Inter99 Study (without pack-years) 1115 549 (49·2%) 1115 (100%) 47·2 (7·76) 3·26 (0·71) 4·12 (0·92) 0·796 (0·07)
Inter99 Study (with pack-years) 4179 2027 (48·5%) 2307 (55·2%) 45·8 (7·95) 3·21 (0·76) 4·10 (0·97) 0·788 (0·08)
Multi-Ethnic Study of 
Atherosclerosis (MESA)
1323 654 (49·4%) 751 (56·8%) 66·0 (9·8) 2·57 (0·76) 3·51 (0·10) 0·733 (0·08)
The Rotterdam Study (RS) 546 299 (54·8%) 382 (70·0%) 79·4 (5·00) 2·27 (0·68) 3·03 (0·86) 0·750 (0·08)
Total 36,998
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(Supplementary Table 7). There was one gene (LY6G6D) that was 
identified in both analyses. These genes were followed up in 
UK Biobank, with two genes, GPR126 and LTBP4, showing 
evidence of replication in the exonic SKAT analysis (P<3·5×10-6); 
however conditional analyses in UK Biobank showed that 
both these associations were driven by single SNPs, that were 
identified in the single variant association analyses and have 
been previously reported in GWAS of these traits (Supplementary 
Table 6 and Supplementary Table 7).
Functional characterization of novel loci
In order to gain further insight into the six loci identified in our 
analyses of single variant associations (excluding LCT), we 
employed functional annotation and assessed whether identi-
fied SNPs in these regions were associated with gene expression 
levels. One of the identified novel SNPs was nonsynonymous, 
three intronic and two were intergenic. We found evidence that 
three of the SNPs may be involved in cis-acting regulation of the 
expression of several genes in multiple tissues (Supplementary 
Table 8).
SNP rs1200345 in RPAP1 is a nonysynomous variant, pre-
dicted to be deleterious by both SIFT (deleterious) and Polyphen 
(possibly damaging) (Supplementary Table 9); RPAP1 is ubiq-
uitously expressed, with high levels of protein detected in the 
lung (Supplementary Table 10). SNP rs1200345 or proxies 
(r2>0·8) were also found to be amongst the most strongly associ-
ated SNPs with expression levels of RPAP1 in several tissues, 
including lung, and with a further six genes in lung tissue 
(Supplementary Table 8), including TYRO3, one of the TAM 
family of receptor tyrosine kinases. TYRO3 regulates several 
processes including cell survival, migration and differentiation 
and is highly expressed in lung macrophages (Supplementary 
Table 10). Evidence of association with gene expression was 
found at two more of the novel signals (sentinel SNPs rs3849969 
and  rs6088813), implicating a further 16 genes. Of note, in blood 
expression quantitative trait loci (eQTL) databases, a proxy of a 
SNP in complete linkage disequilibrium (r2=1) with rs3849969 
(rs3812637) was an eQTL for plasminogen activator, urokinase 
(PLAU).
Discussion
We undertook an analysis of 68,470 individuals from 23 studies 
with data from the exome array and three lung function traits, 
following up the most significant single SNP and gene-based 
associations in an independent sample of up to 111,556 indi-
viduals. There were six SNPs which reached P<10-5 in the 
discovery stage meta-analysis of single variant associations, and 
subsequently met the Bonferroni corrected significance threshold 
for independent replication (P<1·47×10-3, corrected for 34 SNPs 
being tested). In the combined analyses of our discovery and 
replication analyses, these six SNPs met the exome chip-wide 
significance threshold (P<2·8×10-7). One of the SNPs is in a 
region that has previously been implicated in lung function (near 
KCJN2/SOX9)21, whilst the remaining five SNPs, although all 
common, have not previously been identified in other GWAS of 
lung function. In a recent 1000 Genomes imputed analysis of 



















Atherosclerosis Risk in 
Communities Study (ARIC)
3180 1183 (37·2%) 1680 (59·1%) 53·6 (5·83) 2·48 (0·65) 3·25 (0·82) 0·765 (0·08)
Cardiovascular Health Study (CHS) 624 232 (37·2%) 340 (54·4%) 73·2 (5·49) 1·76 (0·58) 2·48 (0·80) 0·717 (0·11)
Health Aging and Body 
Composition Study (HABC)
943 433 (45·9%) 543 (57·6%) 73·4 (2·90) 1·96 (0·57) 2·61 (0·71) 0·749 (0·09)
Jackson Heart Study (JHS) 2143 793 (36·8%) 688 (31·9%) 52·8 (12·6) 2·43 (0·72) 3·02 (0·86) 0·807 (0·09)
Multi-Ethnic Study of 
Atherosclerosis (MESA)


















UK Biobank 98,657 45,166 (45·8%) 56,404 (57·2%) 56·7 (7·92) 2·75 (0·80) 3·67 (0·98) 0·75 (0·07)
UK Household Longitudinal Study 
(UKHLS) 
7443 3293 (44·2%) 4509 (60·5%) 53·10 
(15·94)
2·89 (0·90) 3·83 (1·08) 0·753 (0·09)
Netherlands Epidemiology of 
Obesity study (NEO) 
5456 2672 (48·0%) 3674 (66·0%) 55·9 (5·9) 3·26 (0·80) 4·26 (1·02) 0·77 (0·07)
Total 111,556
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the present discovery analysis), all of these SNPs showed at least 
suggestive association (2·97×10-3>P>1·28×10-5) with one or 
more lung function trait, but none reached the required 
threshold (P<5×10-6) to be taken forward for replication in that 
analysis12.
We further identified a seventh association with rs2322659 in LCT 
(MAF=23·5%; combined discovery + replication P=1·70×10-9). 
Given SNPs in this region are known to vary in frequency across 
European populations, we cannot dismiss the possibility that this 
association may be confounded by population stratification; hence 
we do not report this signal as a novel lung function locus. For 
SNPs at 7 loci that have been shown to have differences in allele 
frequency between individuals from different regions of the 
UK25, and subsequently European populations (including the 
LCT locus), we undertook a look-up of associations with lung 
function in our discovery analyses. and subsequently across 
European populations26. Aside from the association between the 
LCT locus and FVC, no significant associations were observed 
between SNPs at these loci and any lung function trait, in either 
the analyses restricted to European Ancestry (EA) individuals, 
or in the analysis of EA and African Ancestry (AA) individuals 
combined (Supplementary Table 11); this suggests popula-
tion structure was generally accounted for adequately in our 
analyses.
One of the novel signals was with a nonsynonymous SNP, 
rs1200345 in RPAP1, (MAF=48·8%; P=2·33×10-13), which is 
predicted to be deleterious. This SNP and proxies with r2>0·8 
were also associated with expression in lung tissue of seven 
genes, including RPAP1 and the TAM receptor TYRO3. TAM 
receptors play a role in the inhibition of Toll-like receptors (TLRs)- 
mediated innate immune response by initiating the transcription 
of cytokine signalling genes (SOCS-1 and 3), which limit cytokine 
overproduction and inflammation27,28. It has been shown that 
influenza viruses H5N1 and H7N9 can cause downregula-
tion of Tyro3, resulting in an increased inflammatory cytokine 
response28.
Three further signals were with intronic SNPs in SEC24C 
(MAF=29·4%; P=4·99×10-12), CASC17 (MAF=48·2%; 
P=4·10×10-11), and UQCC1 (MAF=36·7%; P=4·90×10-19). Two 
of these intronic SNPs have previously been implicated in GWAS 
of other traits: rs1859962 in CASC17 with prostate cancer29 and 
rs6088813 in UQCC1 with height30. The CASC17 locus, near 
KCNJ2/SOX9 has also previously been implicated in lung func-
tion, showing significant association with FEV1 in a genome-wide 
analysis of gene-smoking interactions; however, this association 
was not formally replicated21. Whilst the individuals utilised in 
the discovery stage of this analysis overlap with those included 
in this previous interaction analysis, the replication stage of the 
present study provides the first evidence of replication for this 
signal in independent cohorts. In the present analysis, there was 
no evidence that the results differed by smoking status.
SNPs rs6088813 in UQCC1 and rs3849969 in SEC24C were 
identified as eQTLs for multiple genes. Whilst our eQTL analysis 
did not include formal tests of colocalisation, a SNP in complete 
linkage disequilibrium with rs3849969 (rs3812637, r2=1) was 
associated with expression of PLAU in blood. The plasmino-
gen activator, urokinase (PLAU) plays a role in fibrinolysis and 
immunity, and with its receptor (PLAUR) is involved in degrada-
tion of the extra cellular matrix, cell migration, cell adhesion and 
cell proliferation31. A study of preterm infants with respiratory 
distress syndrome, a condition characterised by intra-alveolar 
fibrin deposition, found PLAU and its inhibitor SERPINE1 to be 
expressed in the alveolar epithelium, and an increased ratio of 
SERPINE1 to PLAU was associated with severity of disease32. 
Studies in mice have also shown that increased expression of 
Plau may be protective against lung injury, by reducing 
fibrosis33. PLAU has also been found to be upregulated in lung 
epithelial cells subjected to cyclic strain34 and in patients with 
COPD and lung cancer, PLAU was found to be expressed in 
alveolar macrophages and epithelial cells31.
The final two signals were with common intergenic SNPs close 
to LY86 (MAF=36·8%; P=9·74×10-23) and FGF10 (MAF=35·6%; 
P=2·22×10-11). LY86 (lymphocyte antigen 86) interacts with the 
Toll-like receptor signalling pathway, to form a heterodimer, 
when bound with RP10535. The sentinel SNP in the present 
analysis (rs1294421) has previously shown association with 
waist-hip ratio36, whilst an intronic SNP within LY86 (rs7440529, 
r2=0·005 with rs1294421) has been implicated in asthma in two 
studies of individuals of Han Chinese ancestry37,38. FGF10 is a 
member of the fibroblast growth factor family of proteins, and is 
involved in a range of biological processes, including embryonic 
development and morphogenesis, cell growth and repair, tumor 
growth and invasion. Specifically, the FGF10 signalling pathway 
is thought to play an criticial role in the development of the 
lung and in lung epithelial renewal39. A deficiency in Fgf10 
has been demonstrated to lead to a fatal disruption of branching 
morphogenesis during lung development in mice40.
Our discovery analyses included individuals of both EA and 
AA. Two of the identified six novel signals showed inconsistent 
effects in the AA and EA individuals. For these SNPs, the 
associations in AA individuals were not statistically significant, 
and we report associations from the analysis restricted to EA 
individuals only. For the remaining four SNPs similar effects were 
observed in both the EA and AA individuals (Supplementary 
Figure 3). We also examined the effects of the novel SNPs in 
ever smokers and never smokers separately and found these to 
be broadly similar, with the exception of rs1448044 in FGF10, 
which in the discovery analysis showed significant association 
with FVC in ever smokers, whilst showing no association in never 
smokers (P=0·695). However, in our replication stage analyses, 
similar effects were seen in both ever and never smokers for this 
SNP, and the combined analysis of discovery and replication 
stages for this SNP, including both ever and never smokers, met 
the exome chip-wide significance level overall (P=4·22×10-9). We 
also considered whether this signal could be driven by smoking 
behaviour in our discovery stage as our primary analyses in 
SpiroMeta did not adjust for smoking quantity. We undertook a 
look-up of this SNP in the publicly available results of a GWAS 
of several smoking behaviour traits41; there was only weak 
evidence that this SNP was associated with ever versus never 
smoking (P=0·039), and no evidence for association with amount 
smoked (cigarettes per day, P=0·10).
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Through the use of the exome array, we aimed to identify asso-
ciations with low frequency and rare functional variants, thereby 
potentially uncovering some of the missing heritability of lung 
function. However, whilst our discovery analyses identified single 
SNP associations with 23 low frequency variants (Supplementary 
Table 2), we did not replicate any of these findings. Eleven of 
these 23 SNPs we were unable to follow-up in our replication 
studies, due to them either being not genotyped, or monomorphic. 
Overall, limited statistical power is likely to explain our lack of 
convincing single variant associations with rare variants, in 
particular if those variants exhibit only modest effects42. We addi-
tionally investigated the joint effects of low frequency and rare 
variants within genes, on lung function trait, by employing SKAT 
and WST gene-based tests. These analyses identified associations 
with a number of genes that could not attributed to the effect of 
a single SNP. Replication of these gene-based signals proved 
difficult however, as again a number of SNPs included in the 
discovery stage of these analyses were monomorphic, or had 
not been not genotyped in the replication studies. This lead to a 
disparity in the gene unit being tested in our discovery and 
replication samples; hence interpretation of these results was not 
clear-cut. In the end, we were able to replicate only findings with 
common SNPs. This finding is in line with several other stud-
ies of complex traits and exome array data that have been unable 
to report robust associations with low frequency variants43–45 
and it is clear that future studies will require increasingly larger 
sample sizes in order to fully evaluate the effect of variants across 
the allele frequency spectrum. The identification of common SNPs 
remains important, however, as such findings have the potential 
to highlight drug targets46, and these variants collectively could 
have utility in risk prediction.
In our replication analyses using UK Biobank, we applied adjust-
ment for covariates including ancestry principal components, 
before undertaking inverse-normal transformations of the lung 
function phenotypes. Association analyses were then performed 
using these transformed phenotypes. It has recently been 
shown that such transformation has the potential to introduce 
correlations between principal components and phenotypes47; 
we undertook sensitivity analyses for the six reported SNPs 
by repeating the association analyses with phenotypes that 
had been transformed without prior adjustment, with covariate 
adjustment made as part of the SNP-trait association test. We 
found there to be some difference in P-values for some SNP-
trait combinations; however, the six novel SNP associations we 
report all met the replication P-value threshold (P<1·47×10-3) 
in the sensitivity analyses (Supplementary Figure 4). This issue 
may also be relevant to the gene-based tests; however no 
replicated novel gene-based associations were identified in this 
study. Future studies should avoid undertaking adjustment for 
principal components of ancestry prior to trait transformation, 
in order to avoid this potential bias.
This study has identified six common SNPs, independent to 
signals previously implicated in lung function. Additional 
interrogation of these loci could lead to greater understanding of 
lung function and lung disease, and could provide novel targets 
for therapeutic interventions.
Methods
Study design, cohorts and genotyping
The SpiroMeta analysis included 23,751 individuals of EA from 
11 studies, and the CHARGE analysis comprised 36,998 EA 
individuals and a further 7,721 individuals of AA from 12 
studies. Follow-up analyses were conducted in an independent 
sample of up to 111,556 individuals from UK Biobank (2015 
interim release), the UK Household Longitudinal Study (UKHLS) 
and the Netherlands Epidemiology of Obesity (NEO) Study 
(Figure 1). All studies (excluding UK Biobank) were genotyped 
using either the Illumina Human Exome BeadChip v1 or the 
Illumina Infinium HumanCoreExome-12 v1·0 BeadChip. UK 
Biobank samples were genotyped using the Affymetrix Axiom UK 
BiLEVE or UK Biobank arrays.
Statistical analyses
Consortium level analyses: Within the SpiroMeta Consortium, 
each study contributing to the discovery analyses calculated 
single-variant score statistics, along with covariance matrices 
describing correlations between variants, using RAREMETAL-
WORKER48 or rvtests49. For each trait, these summary statistics 
were generated separately in ever and never smokers. Traits were 
adjusted for sex, age, age2 and height, and  inverse normally 
transformed prior to association testing. For studies with unrelated 
individuals, SNP-trait associations were tested using linear 
models, with adjustments made for the first 10 ancestry principal 
components, whilst studies with related individuals utilised linear 
mixed models to account for familial relationships and underlying 
population structure.
Within the CHARGE Consortium, each study generated equiva-
lent summary statistics using the R package SeqMeta50. For each 
trait, summary statistics were generated in ever and never 
smokers separately, and in all individuals combined. The untrans-
formed traits were used for all analyses, adjusted for smoking sta-
tus and pack-years, age, age2, sex, height, height2, centre/cohort. 
Models for FVC were additionally adjusted for weight. Linear 
regression models, with adjustment for principal components 
of ancestry were used for studies with unrelated individuals, and 
linear mixed models were used for family-based studies.
Within each consortium we used the score statistics and variance-
covariance matrices generated by each study to construct both 
single variant and gene-based tests using either RAREMETAL48 
(SpiroMeta) or SeqMeta50 (CHARGE). For single variant 
associations, score statistics were combined in fixed effects 
meta-analyses. Two gene-based tests were constructed: first, the 
Weighted Sum Test (WST) using Madsen Browning weightings23, 
and secondly, the Sequence Kernel Association Test (SKAT)24. 
We performed the SKAT and WST tests using two subsets of 
SNPs: 1) including all SNPs with an overall consortium-wide 
MAF<5% that were annotated as splicing, stopgain, stoploss, or 
frameshift (loss of function [LOF] analysis), and 2) including 
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Figure 1. Study design.
all SNPs meeting the LOF analysis criteria in addition to all 
other nonsynonymous variants with consortium wide MAF<5% 
(exonic analysis). Variants were annotated to genes using 
dbNSFP v2·651 on the basis of the GRCh37/hg19 database.
For both single variant and gene-based associations, 
consortium-level results were generated for ever smokers and 
never smokers separately, and in all individuals combined. Within 
the CHARGE Consortium, results were combined separately for 
the EA and AA studies and also in a trans-ethnic analysis of both 
ancestries.
Combined meta-analysis: The single variant association results 
from the SpiroMeta and CHARGE consortia were combined as 
follows: The genomic inflation statistic (λ) was calculated for 
SNPs with consortium-wide MAF>1%; where λ had a value 
greater than one, genomic control adjustment was applied to the 
consortium level P-values. The consortium-level results were 
then combined using sample size weighted z-score meta-analysis. 
The λ was again calculated for the meta-analysis results 
and genomic control applied, as appropriate. λ values at the 
consortium and meta-analysis level are shown in Supplementary 
Table 13. Since we were interested in identifying low frequency 
and rare variants, we applied no MAF or minor allele count 
(MAC) filter. We identified SNPs of interest as those with an 
overall P<10-5 and a consistent direction of effect and P<0·05 
observed in both consortia. Rather than using a strict Bonferroni 
correction for defining the significance threshold, we adopted 
the more lenient P<10-5 threshold in order to increase the power 
to detect variants with modest effect in our discovery analyses, 
whilst the requirement for consistency in results from the two 
consortia aimed to limit false positives. All SNPs meeting these 
thresholds were followed up in independent replication cohorts. 
Where we identified a SNP within 1Mb of a previously identified 
SpiroMeta:Meta-analysis of
FEV1, FVC and FEV1/FVC in
23,751 EA individuals from 
11 Studies.
CHARGE: Meta-analysis of
FEV1, FVC and FEV1/FVC in
36,998 EA and 7721 AA
individuals from 12 studies.
Overall Meta-analysis of FEV1, FVC and FEV1/FVC in 60,749 EA










34 SNPs selected with P<10-5
with at least one trait in
combined meta-analysis and
P<0.05 in both consortium -
level analysis.
SNPs followed up in an
independent sample of up to
111,556 individuals from UK
Biobank, UKHLS and NEO.
6 SNPs meeting exome chip-
wide significance (P<2.8×10-7)
overall identified.
Results from discovery meta-analysis and replication analysis
combined to give overall result.
0 Genes meeting exome chip-
wide significance (P<3-5×10-6)
overall identified.
Genes followed up in an
independent sample of up to
98,657 individuals from UK
Biobank.
27 Genes selected with P<10-4
with at least one trait in
combined meta-analysis and
P<0.05 in both consortium -
level analysis.
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lung function SNP, we deemed the SNP to represent an 
independent signal if it had r2<0·2 with the known SNP, and if 
it retained a P <10-5, when conditional analyses were carried 
out with the known SNP, or a genotyped proxy, using data 
from the SpiroMeta Consortium, or UK Biobank. Our primary 
meta-analysis included all individuals; we additionally carried 
out analyses in smoking subgroups (ever and never smokers), 
and in the subgroup of individuals of European ancestry only.
For genes which contained at least 2 polymorphic SNPs in both 
consortia, we combined the results of the consortium level gene 
based tests using either z-score meta-analysis (for the WST 
analysis) or Fisher’s Method for combining P-values (in the 
case of SKAT). We identified genes of interest as those with 
P<0·05 observed in both consortia and an overall P<10-4, thresh-
olds again chosen to limit both false positive and false negative 
findings. As in the analyses of single variant associations, our 
primary meta-analyses included all individuals, with secondary 
analyses undertaken in smoking and ancestry specific subgroups.
Replication analyses: All SNP and gene-based associa-
tions were followed up for the trait with which they showed the 
most statistically significant association only. For associations 
identified through the smoking subgroup analyses, we followed 
up associations in the appropriate smoking strata; however, no 
ancestry stratified follow-up was undertaken as replication 
studies included only a sufficient number of individuals of 
European Ancestry.
Single variant associations in UK Biobank were tested in ever 
smokers and never smokers separately, and stratified by 
genotyping array (UK BiLEVE array or UK Biobank array) 
using the score test as implemented in SNPTEST v2·5b452. Traits 
were adjusted for age, age2, height, sex, ten principal compo-
nents and pack-years (ever smokers only), and the adjusted traits 
were inverse normally transformed. Correlations between prin-
cipal components and transformed phenotypes may be intro-
duced where adjustment is made prior to transformation. In this 
analysis, we found any introduced correlations to have no impact 
on the conclusion of our replication analyses; however future 
studies should apply transformation of phenotypes prior to 
covariate adjustment, to avoid this issue. For UKHLS, analyses 
were undertaken analogously to the SpiroMeta discovery studies 
using RAREMETALWORKER, while for NEO, analyses were 
undertaken in the same way as was done in the CHARGE 
discovery studies using SeqMeta. The single variant results 
from all replication studies were combined using sample size 
weighted Z-score meta-analysis. Subsequently, we combined 
the results from the discovery and replication stage analyses and 
we report SNPs with overall exome-wide significance of 
P<2·8×10-7 (Bonferroni corrected for the original 179,215 SNPs 
tested).
We followed up genes of interest (P<10-4) using data from 
UK Biobank only. Summary statistics for UK Biobank were 
generated using RAREMETALWORKER, with gene-based tests 
then constructed using RAREMETAL. Finally, we combined the 
results from the discovery analysis with the replication results in 
an overall combined meta-analysis using either z-score meta- 
analysis (WST) or Fisher’s Method (SKAT). We declared 
genes with overall P<3·5×10-6 (Bonferroni corrected for 14,380 
genes tested) in our combined meta-analysis to be statistically 
significant. For these statistically significant genes, we carried 
out additional analyses using the UK Biobank data in which we 
conditioned on the most significantly associated individual SNP 
within that gene, to determine whether this was a true gene-based 
signal, or whether the association could be ascribed to the single 
SNP (if the conditional P<0·01, then association was deemed 
to not be driven by the single SNP).
Characterization of findings
In order to gain further insight into the loci identified in our 
analyses of single variant associations, we assessed whether these 
regions were associated with gene expression levels in various 
tissues (FDR of 5%, or q-value<0·05), by querying a publically 
available blood eQTL database53 and the GTEx project54 for the 
sentinel SNPs, or any proxy (r2>0·8). We further assessed SNPs 
of interest (and proxies) within a lung eQTL resource based on 
non-tumour lung tissues of 1,111 individuals55–57. Descriptions of 
these resources and further details of the look-ups are provided 
in the Supplementary Methods. Moreover, all sentinel SNPs and 
proxies with r2>0.8 were annotated using ENSEMBL’s 
Variant Effect Predictor (VEP)58; potentially deleterious coding 
variants were identified as those annotated as ‘deleterious’ by 
SIFT59 or ‘probably damaging’ or ‘possibly damaging’ by 
PolyPhen-260. For all genes implicated through the expression 
data or functional annotation, we searched for evidence of 
protein expression in the respiratory system by querying the 
Human Protein Atlas61.
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1. Two rare variant tests were chosen and applied to the data as opposed to choosing a combined










2. The authors should explain why there was an inverse normalization of the traits in SpiroMeta but





3. There appear to be very large differences in Effect Allele Frequencies between the discovery
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 3. There appear to be very large differences in Effect Allele Frequencies between the discovery
and replication samples. Do the authors have an explanation for this? This might point to local







4. The eQTL analysis could formally investigate colocalization as opposed to cross-referencing
individual associated SNPs with public repositories, and there are several different methods that







5. In the replication analyses section, it is stated that “Traits were adjusted for age, age , height,
sex, ten principal components and pack-years (ever smokers only), and inverse normally
transformed.” For clarity, the authors should be specific about whether the trait (FEV , FVC, or FEV
/FVC) was inverse normalized first and age, age , sex, 10 PCs were then added as covariates in
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8. The authors should list the MAF alongside the p-values reported in the text for clarity for the
single variant analysis results
MAFs and P-values have now been added to the main text for all reported loci. 
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1. The phenotypes seem to have been adjusted for covariates and ancestry specific principal
components prior to being inverse normally transformed. This transformation has the potential to
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 components prior to being inverse normally transformed. This transformation has the potential to
introduce correlations between principal components and the inverse normally transformed
phenotype (https://www.biorxiv.org/content/early/2017/05/15/137232). Since one of the SNPs
identified as being associated with the phenotype is known to vary in frequency across European
populations, and the authors note that they cannot rule out the effects of population structure on
the identified associations this raises concerns that some of the other associations could also be
artefacts driven by failure to properly account for population stratification. It should explicitly be
mentioned in the methods whether adjustments were made for ancestry specific principal
components prior to inverse normal transforming the phenotype in the SpiroMeta Consortium













2. Indeed, in the replication analysis in UK Biobank principal components were adjusted for prior to
inverse normally transforming the data. Was genotyping chip adjusted for in this cohort (which
should be done in the phenotype - SNP analysis)? The UKBiLEVE chip was enriched for smokers,
which could affect association analyses unless chip is included as a covariate. In addition the
interim data release (which seems to be what is used here - please clarify in the methods whether
the data comes from the interim (2015) or full (2017) data release) featured some discrepancies
between the two chips, which can introduce spurious associations especially if adjustment is not
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3. Why was raw trait used in CHARGE but inverse normalised in SpiroMeta Consortium? This










1. In the discussion, the authors mention that the 6 identified SNPs not attributed to population
structure passed the Bonferroni significance threshold. They then mention that the SNPs ALSO
pass Bonferroni corrected significance thresholds in the replication analysis. This could be






2. The authors mention that correction was made for genomic inflation statistic (λ), but we could
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